Accéder au contenu
Merck

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.

Bioorganic & medicinal chemistry letters (2004-04-28)
Steven D Linton, Teresa Aja, Peter R Allegrini, Thomas L Deckwerth, Jose-Luis Diaz, Bastian Hengerer, Julia Herrmann, Kathy G Jahangiri, Joerg Kallen, Donald S Karanewsky, Steven P Meduna, Kip Nalley, Edward D Robinson, Silvio Roggo, Giorgio Rovelli, Andre Sauter, Robert O Sayers, Albert Schmitz, Robert Smidt, Robert J Ternansky, Kevin J Tomaselli, Brett R Ullman, Christoph Wiessner, Joe C Wu
RÉSUMÉ

Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Oxamyl, PESTANAL®, analytical standard